The iconic LIBRE fragrance family from YSL Beauty welcomes a blazing new addition this season. Prepare for LIBRE FLOWERS & FLAMES, a captivating scent inspired by the resilient beauty of the desert lily and embodying a spirit of fearless femininity.
PARIS, July 29, 2024 /PRNewswire/ -- YSL Beauty is thrilled to announce the launch of LIBRE FLOWERS & FLAMES, a captivating new fragrance that embodies the brand's signature blend of edgy femininity and unrestrained passion. This latest addition to the iconic LIBRE collection draws inspiration from the desert lily, a flower celebrated for its resilience and ability to thrive in the most unforgiving landscapes.
Master Perfumers Anne Flipo and Carlos Benaïm have reimagined the LIBRE structure with a new floral sensuality, the hottest way. A unique desert lily accord blends with a sunkissed coco palm flower accord crafted exclusively for YSL Beauty. These warm and spicy floral accords add a captivating new dimension to the fragrance, intertwining with a radiant heart of tuberose and orange blossom absolute. The result is a scent as bold and fearless as the woman who wears it.
Fronting the fragrance is YSL Beauty global ambassador Dua Lipa, an icon recognized for her own brand of bold femininity and unwavering self-expression. Set against the stark beauty of the Moroccan desert, the accompanying campaign captures the essence of blazing your own trail and embracing a spirit of fiery independence. The first campaign visual is revealed today, featuring Dua Lipa holding a desert lily against the backdrop of a fiery sunset. The full campaign video is set to be revealed on August 15th.
LIBRE FLOWERS & FLAMES will be available in the US from July 30th onwards, both in store and online at yslbeautyus.com.
ABOUT YSL BEAUTY
YSL Beauty gives body and soul to a style. Completely liberated, it asserts itself as a collection of icons, with each creation driven by boldness, youth and the avant-garde. In the wake of Saint Laurent, who showcased the spirit of the times for nearly 40 years, YSL Beauty continues its unbridled love affair with women to create, shape and develop modernity. No compromise. Your own rules. Now.
http://www.yslbeauty.com
https://www.instagram.com/yslbeauty/
Media Contact : Laura STEFFANUT; laura.steffanut@loreal.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
DUA LIPA FRONTS NEW YSL BEAUTY LIBRE FLOWERS & FLAMES CAMPAIGN
DUA LIPA FRONTS NEW YSL BEAUTY LIBRE FLOWERS & FLAMES CAMPAIGN
New capabilities and simple, standard site experience cut trial time and expense
Fixed price implementation to get up and running quickly
Industry advances to connected trials as
seven of the top 20 biopharmas adopt Veeva Site Connect
SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced, in a major step forward for clinical trial execution, the newest release of Veeva Site Connect, adding powerful new capabilities and a streamlined site-centric experience to simplify and standardize sponsor-site collaboration. With Veeva Site Connect, sponsors reduce the time and effort of site start-up, study conduct, and closeout for higher-quality trials at a significantly lower cost.
"By standardizing how information is shared across all sites in one application with Veeva Site Connect, we aim to save time and effort that can be focused on treating patients," said a clinical operations excellence leader at a top 20 biopharma. "Our goal is to eliminate manual handoffs and inefficiencies for faster site start-up, more efficient monitoring, and simplified study closeout."
To deliver better trial execution in less time, the expansion of Veeva Site Connect includes major application and implementation advances.
"I would be ecstatic if all our sponsors use Veeva Site Connect. It gives sites a much more efficient way to collaborate with sponsors, maintain regulatory compliance, and get critical therapies to patients faster," said Alisha Garibaldi, CEO, Skylight Health Research. "The less time we spend doing administrative work in systems, the more time we have to execute trials and help patients."
"By implementing Veeva Site Connect for our safety letter distribution process, we anticipate achieving a significant reduction in manual processing while enhancing oversight and compliance," said Marta Jureczko-Hinzmann, head of global clinical solution services at AstraZeneca. "Sharing safety letters across all sites globally within a single application will allow us to harmonize the entire process across the company and optimize how we allocate valuable resources."
Veeva Site Connect is part of Veeva Clinical Platform, the complete and connected solution supporting patients, sites, and sponsors. Veeva Site Connect plays a critical role as the industry moves to simplify and standardize site collaboration, and seven of the top 20 biopharmas have already adopted Veeva Site Connect to streamline trials.
See the Veeva Site Connect demo and learn more at Veeva R&D and Quality Summit October 15 in Korea, where top biopharmas will share how they use Veeva Site Connect to simplify trial execution for greater quality and speed.
Additional Information
For more on Veeva Site Connect, visit: veeva.com/VeevaSiteConnect
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024 and in our subsequent SEC filings, which you can access at sec.gov.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors
